1. Home
  2. OFG vs CAPR Comparison

OFG vs CAPR Comparison

Compare OFG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFG Bancorp

OFG

OFG Bancorp

HOLD

Current Price

$38.68

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$30.62

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFG
CAPR
Founded
1964
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2012
2011

Fundamental Metrics

Financial Performance
Metric
OFG
CAPR
Price
$38.68
$30.62
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$43.40
$44.63
AVG Volume (30 Days)
271.5K
1.2M
Earning Date
04-22-2026
03-12-2026
Dividend Yield
3.62%
N/A
EPS Growth
8.27
N/A
EPS
4.58
N/A
Revenue
N/A
N/A
Revenue This Year
$10.14
N/A
Revenue Next Year
$1.38
$31.86
P/E Ratio
$8.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.15
$4.30
52 Week High
$46.11
$40.37

Technical Indicators

Market Signals
Indicator
OFG
CAPR
Relative Strength Index (RSI) 35.82 58.59
Support Level $37.79 $25.33
Resistance Level $43.03 $36.49
Average True Range (ATR) 1.03 2.03
MACD -0.15 0.12
Stochastic Oscillator 25.96 49.96

Price Performance

Historical Comparison
OFG
CAPR

About OFG OFG Bancorp

OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: